What is the appropriate workup for systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 17, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Workup for SLE and Antiphospholipid Syndrome

For suspected SLE, obtain ANA by immunofluorescence on HEp-2 cells at ≥1:80 titer as the mandatory entry test, followed by anti-dsDNA, complement levels (C3/C4), and complete blood count; for suspected APS, test for lupus anticoagulant, anticardiolipin antibodies (IgG/IgM), and anti-β2-glycoprotein I antibodies (IgG/IgM), with repeat testing at ≥12 weeks to confirm persistence.

SLE Diagnostic Workup

Initial Screening

  • ANA testing is the essential entry criterion - ANA by immunofluorescence on HEp-2 cells at titer ≥1:80 has 97.8% sensitivity for SLE 1. Without a positive ANA (or equivalent solid-phase assay), SLE classification cannot proceed. This is non-negotiable.

Core Serological Panel (if ANA positive)

  • Anti-dsDNA antibodies - correlates with disease activity and renal involvement 2
  • Complement levels (C3 and C4) - low levels indicate active disease and predict flares 2
  • Anti-Sm antibodies - highly specific for SLE 3
  • Anti-Ro/SSA and anti-La/SSB antibodies - essential if pregnancy is considered (0.7-2% risk of congenital heart block) 4
  • Anti-RNP antibodies - part of extractable nuclear antigen (ENA) panel 3

Additional Useful Tests

  • Anti-C1q antibodies - useful for predicting renal flares, particularly in anti-dsDNA negative patients 3
  • Anti-nucleosome antibodies - helpful for diagnosis and monitoring in dsDNA-negative patients 3

Hematologic Assessment

  • Complete blood count - screen for cytopenias (leukopenia, lymphopenia, thrombocytopenia, hemolytic anemia) 2

Renal Evaluation

  • Urinalysis with microscopy - assess for proteinuria and active sediment 2
  • Serum creatinine and blood urea nitrogen - evaluate renal function 4
  • 24-hour urine protein or spot urine protein-to-creatinine ratio 2
  • Renal biopsy - indicated when lupus nephritis is suspected for classification and treatment planning 2

Antiphospholipid Syndrome Workup

Triple Test Approach (Mandatory)

The cornerstone of APS diagnosis requires testing for all three antibody types 5:

  1. Lupus anticoagulant (LA) - most strongly associated with thrombosis and pregnancy morbidity 6, 7

    • Use dilute Russell's viper venom time (dRVVT) and/or activated partial thromboplastin time (aPTT)-based assays
    • Include mixing studies and confirmatory tests with phospholipid neutralization
  2. Anticardiolipin antibodies (aCL) - IgG and IgM isotypes by ELISA 5

    • Moderate titer: ≥40 Units
    • High titer: ≥80 Units
    • IgG isotype more strongly associated with thrombosis than IgM 7
  3. Anti-β2-glycoprotein I antibodies (aβ2GPI) - IgG and IgM isotypes by ELISA 5

    • Same titer thresholds as aCL (≥40 Units moderate, ≥80 Units high)
    • IgG isotype shows stronger clinical associations 7

Critical Testing Requirements

  • Repeat testing at ≥12 weeks - persistence of antibodies is mandatory for APS classification 5
  • Test during stable clinical state - avoid testing during acute thrombosis or active infection when possible
  • All three tests must be performed - LA performs better than isolated aCL or aβ2GPI testing 7

Risk Stratification by Antibody Profile

The antibody profile determines thrombotic risk 4:

High-risk profile:

  • Lupus anticoagulant positive (strongest predictor)
  • Multiple antibody positivity (LA + aβ2GPI + aCL)
  • Moderate-to-high titers (≥40 Units)
  • Triple positivity: LA + aβ2GPI + anti-PS/PT shows OR 23.2 for clinical events 6

Lower-risk profile:

  • Single antibody positivity
  • Low titers
  • Isolated IgM positivity

Emerging Tests (Consider in Seronegative Cases)

  • Anti-phosphatidylserine/prothrombin (aPS/PT) antibodies - IgG and IgM isotypes improve diagnostic accuracy, especially when combined with LA and aβ2GPI (OR 3.73 for APS) 6, 8, 9
  • Particularly useful in SLE patients who are seronegative on conventional assays but have high clinical suspicion 8, 9

Combined SLE-APS Evaluation

When to Test for Both

Test for antiphospholipid antibodies in all SLE patients because 4, 2:

  • Presence of aPL/APS is a major risk factor for adverse outcomes (Level 1A evidence)
  • 30-40% of SLE patients have positive aPL
  • Changes management regarding anticoagulation and pregnancy counseling

Integrated Testing Panel for SLE Patients

  1. ANA (entry criterion)
  2. Anti-dsDNA, complement (C3/C4)
  3. Complete aPL panel (LA, aCL IgG/IgM, aβ2GPI IgG/IgM)
  4. Anti-Ro/SSA and anti-La/SSB (if female of childbearing age)
  5. Complete blood count
  6. Renal function tests and urinalysis

Monitoring Parameters

For established SLE with or without APS 4, 2:

  • Disease activity assessment - use validated indices
  • Renal function - creatinine, urinalysis every visit
  • Serological markers - C3/C4, anti-dsDNA for flare prediction
  • Blood pressure monitoring - essential in both conditions 4

Common Pitfalls to Avoid

  1. Do not diagnose SLE without positive ANA - ANA negativity has only 2.2% false-negative rate; reconsider diagnosis 1

  2. Do not test aPL during acute thrombosis - transient positivity can occur; wait for stable state when possible

  3. Do not rely on single positive aPL test - persistence at ≥12 weeks is mandatory 5

  4. Do not use fixed cutoffs for non-ELISA aPL assays - ELISA remains the standard for aCL and aβ2GPI 5

  5. Do not ignore IgA isotypes completely - while not in classification criteria, IgA aCL and aβ2GPI may be relevant in seronegative cases with high clinical suspicion 5

  6. Do not forget to assess for lupus anticoagulant - LA is the strongest predictor of thrombosis, superior to aCL or aβ2GPI alone 6, 7

  7. In SLE patients with negative conventional aPL but high clinical suspicion for APS, consider testing for aPS/PT antibodies 6, 8, 9

References

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.